BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29545102)

  • 1. Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.
    Yu T; Zhang Y; Kerekes AD; Tagat JR; Doll RJ; Xiao Y; Esposite S; Hruza A; Belanger DB; Voss M; Rainka MP; Basso A; Liu M; Liang L; Sui N; Prelusky D; Rindgen D; Zhang L
    Bioorg Med Chem Lett; 2018 May; 28(8):1397-1403. PubMed ID: 29545102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
    Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
    J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
    Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
    Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
    Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
    Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Lorenzo M; Rodríguez A; Rivero V; Martín JI; Saluste CG; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán M; Alfonso P; García-Serelde B; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Pastor J
    Bioorg Med Chem Lett; 2012 May; 22(10):3460-6. PubMed ID: 22520259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.
    Rawson TE; Rüth M; Blackwood E; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Georges GJ; Goller B; Halladay J; Hunsaker T; Kleinheinz T; Krell HW; Li J; Liang J; Limberg A; McNutt A; Moffat J; Phillips G; Ran Y; Safina B; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhou A; Zhu BY; Rüger P; Cochran AG
    J Med Chem; 2008 Aug; 51(15):4465-75. PubMed ID: 18630890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
    Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
    Bavetsias V; Large JM; Sun C; Bouloc N; Kosmopoulou M; Matteucci M; Wilsher NE; Martins V; Reynisson J; Atrash B; Faisal A; Urban F; Valenti M; de Haven Brandon A; Box G; Raynaud FI; Workman P; Eccles SA; Bayliss R; Blagg J; Linardopoulos S; McDonald E
    J Med Chem; 2010 Jul; 53(14):5213-28. PubMed ID: 20565112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
    Furqan M; Huma Z; Ashfaq Z; Nasir A; Ullah R; Bilal A; Iqbal M; Khalid MH; Hussain I; Faisal A
    Cell Cycle; 2019 Sep; 18(18):2281-2292. PubMed ID: 31318643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
    Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.
    Ando R; Ikegami H; Sakiyama M; Ooike S; Hayashi M; Fujino Y; Abe D; Nakamura H; Mishina T; Kato H; Iwase Y; Tomozane H; Morioka M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4709-11. PubMed ID: 20573509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
    Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
    Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
    Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
    J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B.
    Gyulavári P; Szokol B; Szabadkai I; Brauswetter D; Bánhegyi P; Varga A; Markó P; Boros S; Illyés E; Szántai-Kis C; Krekó M; Czudor Z; Őrfi L
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3265-3270. PubMed ID: 30143423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAR156497, an exquisitely selective inhibitor of aurora kinases.
    Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
    J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.